Key statistics dashboard for ABVC BioPharma, Inc. (ABVC). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on creating novel drugs and medical devices to address critical, underserved healthcare requirements across the United States. The company's pipeline includes several key candidates: ABV-1501, currently undergoing Phase I/II clinical trials, is being developed as a combination treatment for triple-negative breast cancer.
Stock Data
| Price | $1.08 |
| Market Cap | $28M |
| Beta | 0.38 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -3.66 |
| Price / Book | 2.74 |
| P/S | -35.28 |
| P/FCF | -11.48 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 100.00% |
| EBIT Margin | 1035.31% |
| EBITDA Margin | 983.23% |
| Operating Margin | 918.55% |
| Net Margin | 992.85% |
Financial Health
| Current Ratio | 0.07 |
| Quick Ratio | 0.07 |
| Cash Ratio | 0.01 |
| Debt / Equity | 0.17 |
| Debt / Assets | 9.09% |
| Interest Coverage | -47.11 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -2.61 |
Per-Share Data
| Revenue per share | -0.03 |
| Book Value per share | 0.47 |
| Cash per share | 0.00 |
| FCF per share | -0.09 |
| Tangible Book Value per share | 0.47 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Related companies: ATNM · FGEN · GRCE · JUNS · LTRN · LVTX · PDSB
Explore sector: Healthcare · Biotechnology
More sections of ABVC: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks